KR20230022882A - 라벡시모드의 결정성 형태를 제조하는 방법 - Google Patents

라벡시모드의 결정성 형태를 제조하는 방법 Download PDF

Info

Publication number
KR20230022882A
KR20230022882A KR1020227045213A KR20227045213A KR20230022882A KR 20230022882 A KR20230022882 A KR 20230022882A KR 1020227045213 A KR1020227045213 A KR 1020227045213A KR 20227045213 A KR20227045213 A KR 20227045213A KR 20230022882 A KR20230022882 A KR 20230022882A
Authority
KR
South Korea
Prior art keywords
chloro
dimethyl
salt
quinoxaline
rabeximod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045213A
Other languages
English (en)
Korean (ko)
Inventor
울프 비요르크룬드
Original Assignee
사익손 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사익손 아베 filed Critical 사익손 아베
Publication of KR20230022882A publication Critical patent/KR20230022882A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
KR1020227045213A 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 제조하는 방법 Pending KR20230022882A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP20179277 2020-06-10
EP20179279.3 2020-06-10
EP20179239 2020-06-10
EP20179239.7 2020-06-10
EP20179279 2020-06-10
EP20179277.7 2020-06-10
EP20180706.2 2020-06-18
EP20180706 2020-06-18
PCT/EP2021/065694 WO2021250197A1 (en) 2020-06-10 2021-06-10 Method for preparing a crystalline form of rabeximod

Publications (1)

Publication Number Publication Date
KR20230022882A true KR20230022882A (ko) 2023-02-16

Family

ID=76305939

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227045213A Pending KR20230022882A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 제조하는 방법
KR1020227045212A Pending KR20230022881A (ko) 2020-06-10 2021-06-10 류마티스 관절염의 치료에서의 라벡시모드
KR1020227045211A Pending KR20230022880A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 포함하는 경구 제형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227045212A Pending KR20230022881A (ko) 2020-06-10 2021-06-10 류마티스 관절염의 치료에서의 라벡시모드
KR1020227045211A Pending KR20230022880A (ko) 2020-06-10 2021-06-10 라벡시모드의 결정성 형태를 포함하는 경구 제형

Country Status (8)

Country Link
US (3) US12594274B2 (cg-RX-API-DMAC7.html)
EP (3) EP4164616A1 (cg-RX-API-DMAC7.html)
JP (3) JP2023529001A (cg-RX-API-DMAC7.html)
KR (3) KR20230022882A (cg-RX-API-DMAC7.html)
CN (4) CN115697308A (cg-RX-API-DMAC7.html)
AU (3) AU2021290174A1 (cg-RX-API-DMAC7.html)
CA (3) CA3181637A1 (cg-RX-API-DMAC7.html)
WO (3) WO2021250199A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023529001A (ja) 2020-06-10 2023-07-06 シクソン エービー 結晶形のラベキシモドを含む経口製剤
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (sv) 1986-01-21 1986-01-21 Lundblad Leif Substituerade indolokinoxaliner
SE504289C2 (sv) * 1994-06-23 1996-12-23 Leif J I Lundblad Användning av vissa indolo-2,3b-kinoxaliner för framställning av ett läkemedel för inhibering av enzymet HIV-integras
JPH08165278A (ja) 1994-12-14 1996-06-25 Kawaken Fine Chem Co Ltd 1−置換トリプタミン化合物の製造方法
SE504862C2 (sv) 1994-12-27 1997-05-20 Leif J I Lundblad Användning av vissa indolo-§2,3b¤-kinoxaliner för framställning av ett läkemedel för skydd av DNA i initieringsfasen och/eller promotionsfasen av karcinogenes och för förhindrande av oxidativ stress i patienter med sjukdomar relaterade till fria radikaler
DE19516804A1 (de) * 1995-05-08 1996-11-14 Hoechst Ag Isoindolinpigmente auf Basis von Aminochinoxalindionen
SE516067C2 (sv) 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6333327B2 (en) 2000-02-18 2001-12-25 Leif J. I. Lundblad Method for the treatment of Multiple Sclerosis
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
ATE382623T1 (de) * 2004-06-09 2008-01-15 Hoffmann La Roche Octahydropyrrolo(3,4-c)pyrrolderivate und deren verwendung als antivirale mitteln
SE527639C2 (sv) 2004-06-17 2006-05-02 Oxypharma Ab Alkylsubstituerade indolokinoxaliner
CN101558038B (zh) * 2006-11-30 2013-05-01 国立大学法人东京工业大学 姜黄素衍生物
CN102115457B (zh) 2011-03-05 2012-11-21 太原理工大学 一种n-乙基咔唑的制备方法
WO2013182905A2 (en) * 2012-06-05 2013-12-12 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
WO2014140321A1 (en) 2013-03-15 2014-09-18 Vironova Ab Antiviral indolo[2,3-b]quinoxaline
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
CN105061432B (zh) 2015-07-16 2017-09-29 河北大学 6H‑吲哚[2,3‑b]喹喔啉衍生物、药物组合物及其制备和应用
TWI721483B (zh) * 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
WO2021250196A1 (en) 2020-06-10 2021-12-16 Cyxone Ab New use of rabeximod
JP2023529001A (ja) 2020-06-10 2023-07-06 シクソン エービー 結晶形のラベキシモドを含む経口製剤
US11643415B1 (en) * 2021-12-09 2023-05-09 Cyxone Ab Rabeximod compounds

Also Published As

Publication number Publication date
CN115698010A (zh) 2023-02-03
CN115697308A (zh) 2023-02-03
KR20230022880A (ko) 2023-02-16
JP2023529001A (ja) 2023-07-06
CA3181646A1 (en) 2021-12-16
KR20230022881A (ko) 2023-02-16
EP4164650A1 (en) 2023-04-19
AU2021290173A1 (en) 2023-02-09
EP4165043A1 (en) 2023-04-19
US20220133717A1 (en) 2022-05-05
JP2023533662A (ja) 2023-08-04
AU2021290174A1 (en) 2023-02-09
CN115768431A (zh) 2023-03-07
CA3181629A1 (en) 2021-12-16
US12673056B2 (en) 2026-07-07
US20230227455A1 (en) 2023-07-20
CA3181637A1 (en) 2021-12-16
WO2021250197A1 (en) 2021-12-16
WO2021250204A1 (en) 2021-12-16
JP2023529877A (ja) 2023-07-12
EP4164616A1 (en) 2023-04-19
US12594274B2 (en) 2026-04-07
US20230227456A1 (en) 2023-07-20
CN120383602A (zh) 2025-07-29
AU2021289006A1 (en) 2023-02-09
WO2021250199A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
JP6985367B2 (ja) 新規化合物および方法
AU2008321575B2 (en) A process for the preparation of (3aR,4S, 6R, 6aS)-6-amino-2, 2- dimethyltetrahydro-3aH-cyclopenta[d] [1,3] dioxol-4-ol dibenzoyl-L-tartrate and to products of said process
EP2470182A1 (en) Synthesis of a neurostimulative piperazine
CN107922352A (zh) 制备蛋白质脱乙酰酶抑制剂的方法
JP2023529877A (ja) 結晶形のラベキシモドの調製方法
KR20020073495A (ko) 시탈로프람의 제조 방법
KR20260062870A (ko) Fmoc-lys(ivdde)-oh의 제조방법
JP2009513569A (ja) キノリン化合物の合成のための新規な化学的方法
KR20140034807A (ko) 7-클로로-4-(피페라진-1-일)-퀴놀린의 합성을 위한 신규 방법
KR101457453B1 (ko) 게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
WO2016116074A1 (en) A method of producing highly pure rilpivirine and its salts
CN113956267B (zh) 一种抗肿瘤药物依喜替康甲磺酸盐的制备方法
CN113227075A (zh) 用于产生n,n’-双[2-(1h-咪唑-4-基)乙基]丙二酰胺的新方法
JPH0335317B2 (cg-RX-API-DMAC7.html)
CN109369618B (zh) 一锅烩制备2-氯-5-((2-(硝基亚甲基)咪唑啉-1-基)甲基)吡啶的方法
CN114394941A (zh) 一种2,4-二氨基-6-氯嘧啶的制备方法
CN113045446A (zh) 一种转肽酶生化检验试剂底物的制备方法
CN118930551B (zh) 制备β-氨基吡嗪乙酸酯的方法
CN109851557B (zh) 一种西他沙星有关物质d-3的制备方法
CN114605494B (zh) 一种阿加曲班及其中间体的制备方法
CN119613290A (zh) 一种1-氨基-2-氰基-1-环戊烯的合成方法
US20050159596A1 (en) Cyclic compounds and their use as complex ligands
US7482476B2 (en) Process for the preparation of 5-cyanophthalide starting from 5-carboxyphthalide
JP2025511664A (ja) 4-[5-[ビス(2-クロロエチル)アミノ]-1-メチル-1H-ベンゾ[d]イミダゾール-2-イル]酪酸アルキルエステル及びホルミル化誘導体の調製方法
EA037179B1 (ru) Способ получения энантиомеров пирлиндола и их солей

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000